Advancements in Dermatology: A Weekly Review
Dermatologia e Venerologia
Dermatology and Venereology Insights: Latest Guidelines and Treatments
This episode reviews the latest European guidelines for dermatological conditions including basal cell carcinoma, psoriatic arthritis, atopic eczema, and actinic keratoses, discussing updated treatment approaches and clinical recommendations.
Bibliography
1. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.
Authors: Wolchok JD, Chiarion-Sileni V, Rutkowski P, et al.
Journal: The New England journal of medicine
PMID: 39282897
DOI: 10.1056/NEJMoa2407417
2. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
Authors: Tawbi HA, Schadendorf D, Lipson EJ, et al.
Journal: The New England journal of medicine
PMID: 34986285
DOI: 10.1056/NEJMoa2109970
3. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
Authors: Larkin J, Chiarion-Sileni V, Gonzalez R, et al.
Journal: The New England journal of medicine
PMID: 26027431
DOI: 10.1056/NEJMoa1504030
4. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
Authors: Patel SP, Othus M, Chen Y, et al.
Journal: The New England journal of medicine
PMID: 36856617
DOI: 10.1056/NEJMoa2211437
5. Systemic Photoprotection in Melanoma and Non-Melanoma Skin Cancer.
Authors: Hyeraci M, Papanikolau ES, Grimaldi M, et al.
Journal: Biomolecules
PMID: 37509103
DOI: 10.3390/biom13071067
Authors: Wolchok JD, Chiarion-Sileni V, Rutkowski P, et al.
Journal: The New England journal of medicine
PMID: 39282897
DOI: 10.1056/NEJMoa2407417
2. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
Authors: Tawbi HA, Schadendorf D, Lipson EJ, et al.
Journal: The New England journal of medicine
PMID: 34986285
DOI: 10.1056/NEJMoa2109970
3. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
Authors: Larkin J, Chiarion-Sileni V, Gonzalez R, et al.
Journal: The New England journal of medicine
PMID: 26027431
DOI: 10.1056/NEJMoa1504030
4. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
Authors: Patel SP, Othus M, Chen Y, et al.
Journal: The New England journal of medicine
PMID: 36856617
DOI: 10.1056/NEJMoa2211437
5. Systemic Photoprotection in Melanoma and Non-Melanoma Skin Cancer.
Authors: Hyeraci M, Papanikolau ES, Grimaldi M, et al.
Journal: Biomolecules
PMID: 37509103
DOI: 10.3390/biom13071067
